BioRegenx, Inc.
BRGX
$0.0129
$0.001917.27%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -831.70K | -633.20K | -503.90K | 22.20K | 1.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -831.70K | -633.20K | -503.90K | 22.20K | 1.00M |
| Cost of Revenue | -155.60K | -46.70K | -45.90K | 100.40K | 307.30K |
| Gross Profit | -675.90K | -586.30K | -457.90K | -78.20K | 697.60K |
| SG&A Expenses | 1.38M | 4.18M | 4.37M | 2.35M | 2.56M |
| Depreciation & Amortization | 1.63M | 1.07M | 503.70K | 5.90K | 5.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.85M | 5.19M | 4.83M | 2.46M | 2.88M |
| Operating Income | -3.69M | -5.83M | -5.33M | -2.44M | -1.87M |
| Income Before Tax | -4.21M | -6.33M | -5.82M | -2.90M | -1.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.21 | -6.33 | -5.82 | -2.90 | -1.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.21M | -6.33M | -5.82M | -2.90M | -1.74M |
| EBIT | -3.69M | -5.83M | -5.33M | -2.44M | -1.87M |
| EBITDA | -2.04M | -4.75M | -5.13M | -2.43M | -1.87M |
| EPS Basic | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 3.86B | 3.52B | 3.33B | 2.99B | 2.97B |
| Average Diluted Shares Outstanding | 3.86B | 3.52B | 3.33B | 2.99B | 2.97B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
